What is it about?
This systematic review of 53 studies (10848 patients) showed there was a statistical difference in pCR between high and low Ki 67 expression for breast cancer patients who received neoadjuvant chemotherapy. The variations in Ki 67cutoff points and pCR definitions did not change the statistical difference in pCR between high and low Ki 67 expression. Ki 67 could also predict pCR in HR+, HER2+ and triple negative breast cancer patients, those who received NAC containing plus taxanes and anthracyclines only, and those from Asia and Europe, but not in ER- breast cancer patients, those who received taxanes only and those from America. No consensus achieved on the standard values for classifying Ki-67 as high or low, we found 15% and 20% might be good cut-off points, which were due to highest OR values and consistent results across studies and low statistical heterogeneity. We could conclude that Ki 67 might predict the response by pCR and detection of pre-treatment Ki67 could identify patients most likely to benefit from NAC.
Read the Original
This page is a summary of: The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis, Future Oncology, April 2017, Future Medicine, DOI: 10.2217/fon-2016-0420.
You can read the full text:
The following have contributed to this page